Understanding Variability in CAR-T Cell Therapy Kinetics Publication 了解 CAR-T 细胞疗法动力学的变异性 Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates…Certara2025 年 1 月 23 日
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA) On-Demand Webinar 利用基于模型的荟萃分析 (MBMA) 解决药物开发难题 In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…Certara2025 年 1 月 9 日
AI in Life Sciences Finds an Early Success and Will Continue in 2025 Press Coverage AI in Life Sciences Finds an Early Success and Will Continue in 2025 Fran Brown highlights how AI in life sciences drives more precise drug development and reduces…Certara2024 年 12 月 24 日
Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA Poster 临床前数据暴露无法预测双特异性 T 细胞吸引剂在实体瘤适应症中的临床生理活性剂量;是否有更好的衡量标准?— 来自小型机制性 MBMA 的启示 Certara2024 年 12 月 11 日
Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development Video Piet van der Graaf 谈人工智能和人工智能辅助药物研发方法 At the 2024 AAPS PharmSci 360 conference, Bioanalysis Zone interviewed Piet van der Graaf, Senior…Certara2024 年 12 月 10 日
Advancing pharmacometrics in Africa – Transition from capacity development toward job creation Publication 推动非洲定量药理学的发展 — 从能力建设向创造就业过渡 This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…Certara2024 年 12 月 9 日
Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi Poster GalNAc-siRNA 偶联物 Plozasiran(ARO-APOC3)治疗严重高甘油三酯血症患者的群体药代动力学-药效学(K-PD)建模 Certara2024 年 11 月 22 日
健康受试者中TBA-7371的群体药代动力学建模揭示了清除率的表观自身诱导现象,并预测了结核分枝杆菌感染受试者的药代动力学 海报 健康受试者中TBA-7371的群体药代动力学建模揭示了清除率的表观自身诱导现象,并预测了结核分枝杆菌感染受试者的药代动力学 Certara2024 年 11 月 22 日
Impacts of dose titration on logistic exposure-response in simulated flexible-dose clinical trials Poster 剂量滴定对模拟灵活剂量临床试验中逻辑暴露-反应关系的影响 Certara2024 年 11 月 22 日
Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma Poster 复发/难治性多发性骨髓瘤患者 Belantamab Mafodotin、可溶性B细胞成熟抗原(BCMA)和血清 M-蛋白的群体药代动力学-药效学(PKPD)同步分析 Certara2024 年 11 月 22 日